Lotus Eye Hospital and Institute Valuation

Is LOTUSEYE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LOTUSEYE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LOTUSEYE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LOTUSEYE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LOTUSEYE?

Key metric: As LOTUSEYE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for LOTUSEYE. This is calculated by dividing LOTUSEYE's market cap by their current earnings.
What is LOTUSEYE's PE Ratio?
PE Ratio	94.4x
Earnings	₹14.07m
Market Cap	₹1.33b

LOTUSEYE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.7x
Enterprise Value/EBITDA	26.5x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does LOTUSEYE's PE Ratio compare to its peers?

The above table shows the PE ratio for LOTUSEYE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	48x
543943 Asarfi Hospital	25.6x	n/a	₹1.6b
SANGANI Sangani Hospitals	36.9x	n/a	₹995.4m
MAITREYA Maitreya Medicare	109.8x	n/a	₹2.2b
UNIHEALTH Unihealth Hospitals	19.7x	n/a	₹2.2b
LOTUSEYE Lotus Eye Hospital and Institute	94.4x	n/a	₹1.3b

Price-To-Earnings vs Peers: LOTUSEYE is expensive based on its Price-To-Earnings Ratio (94.4x) compared to the peer average (48x).

Price to Earnings Ratio vs Industry

How does LOTUSEYE's PE Ratio compare vs other companies in the IN Healthcare Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
523696 Fortis Malar Hospitals	2.1x	n/a	US$11.77m
542918 Gian Life Care	4.8x	n/a	US$2.28m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: LOTUSEYE is expensive based on its Price-To-Earnings Ratio (94.4x) compared to the Indian Healthcare industry average (42.6x).

Price to Earnings Ratio vs Fair Ratio

What is LOTUSEYE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LOTUSEYE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	94.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate LOTUSEYE's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Medico Intercontinental

₹612.9m

Trades in pharmaceutical products.

539938

₹61.29

33.1%

-27.8%

Mohini Health & Hygiene

₹911.8m

Engages in the manufacture and sale of health and hygiene products in India.

MHHL

₹50.00

-0.9%

-25.3%

Dr Lalchandani Labs

₹81.2m

Provides diagnostic and related healthcare tests and services in India.

541299

₹18.73

4.1%

-46.5%